Clinical Trials by Drug

Browse recruiting clinical trials organized by investigational drug. For most patients, browsing by disease is the right starting point; drug-anchored pages are useful when you already know which drug you want to learn about.

Data from ClinicalTrials.gov

Antibody-Drug Conjugates (ADCs)

Enhertu (Trastuzumab Deruxtecan / T-DXd / DS-8201)

147 recruiting trials (FDA-approved across 4 cancer types, 8 distinct labels)

Patritumab Deruxtecan (HER3-DXd / U3-1402 / MK-1022)

23 recruiting trials

Padcev (Enfortumab Vedotin / ASG-22ME)

33 recruiting trials (first-in-class Nectin-4 ADC)

HER2-Targeted Antibodies

Ziihera (Zanidatamab / ZW25)

16 recruiting trials (FDA-approved HER2 biparatopic bispecific)

HER2 Tyrosine Kinase Inhibitors

Sevabertinib (Hyrnuo / BAY 2927088)

3 recruiting trials (first oral HER2 TKI for HER2-mutant NSCLC)

CLDN18.2-Targeted Therapies

Vyloy (Zolbetuximab / IMAB362)

First-in-class CLDN18.2 antibody — FDA-approved 2024 (gastric)

T-Cell Engagers (Bispecific Antibodies)

Tarlatamab (Imdelltra)

18 recruiting trials

Teclistamab (Tecvayli / JNJ-64007957)

25 recruiting trials

Iberdomide (Zenbexus, CC-220)

14 recruiting trials (FDA-approved Aug 2026)

Talquetamab (Talvey / JNJ-64407564)

17 recruiting trials

Tebentafusp (Kimmtrak / tebentafusp-tebn / IMCgp100)

11 recruiting trials (FDA-approved)

RP1 (Tudriqev / vusolimogene oderparepvec)

2 recruiting trials (FDA-approved)

Bispecific Checkpoint Inhibitors

Ivonescimab (Yiruixi / AK112 / SMT112)

62 recruiting trials

Rilvegostomig (AZD2936)

12 recruiting trials

Cadonilimab (Kaitanni / AK104)

88 recruiting trials

TROP2 ADCs

Trodelvy (Sacituzumab Govitecan / IMMU-132)

50 recruiting trials (FDA-approved)

Datroway (Datopotamab Deruxtecan / Dato-DXd / DS-1062)

16 recruiting trials (FDA-approved)

PSMA Radioligand Therapy

Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan / 177Lu-PSMA-617)

48 recruiting trials (FDA-approved)

KRAS G12C Inhibitors

Krazati (Adagrasib / MRTX849)

7 recruiting trials (FDA-approved)

Pan-RAS Inhibitors

Daraxonrasib (RMC-6236)

15 recruiting trials (RAS(ON) franchise)

IDH Inhibitors

Voranigo (Vorasidenib) & the IDH-Inhibitor Class

59 recruiting trials (IDH1/IDH2-mutant glioma, AML, cholangiocarcinoma)

Arginine Depletion

ADI-PEG 20 (Pegargiminase)

6 recruiting trials

PARP Inhibitors

Lynparza (Olaparib)

56 recruiting trials (FDA-approved)

Zejula (Niraparib)

24 recruiting trials (FDA-approved)

CDK4/6 Inhibitors

Ibrance (Palbociclib)

33 recruiting trials (FDA-approved)

Oral SERDs (Selective Estrogen Receptor Degraders)

Giredestrant (GDC-9545)

Recruiting trials (investigational — under FDA Priority Review)

Camizestrant (Etcamah / AZD9833)

5 recruiting trials (next-gen oral SERD; FDA-approved Sep 2026, ctDNA-guided ESR1 switch)

PI3K/mTOR Inhibitors

Gedatolisib (Revtorpyk / PF-05212384)

3 recruiting trials (first-in-class pan-PI3K/mTOR inhibitor)

Multikinase Inhibitors (VEGFR / FGFR / RET / KIT)

Lenvima (Lenvatinib / E7080)

~100 recruiting trials (FDA-approved across 4 cancer types)

Zanzalintinib (XL092)

36 recruiting trials (investigational, not FDA-approved)

ROS1-Selective Inhibitors

Zidesamtinib (Jideytro / NVL-520)

Pivotal ARROS-1 recruiting (first ROS1-selective TKI)

HIF-2α Inhibitors

Welireg (Belzutifan / MK-6482)

14 recruiting trials (first-in-class HIF-2α inhibitor)

Personalized Cancer Vaccines

Intismeran Autogene (V940 / mRNA-4157)

6 recruiting trials

Looking for a different drug?

Use ClinTrialFinder's AI-powered matching to search by drug name, disease, or biomarker.

Find Clinical Trials

Browsing by Disease or Mechanism Instead

If you don't know which drug you want, start with the disease-specific trial pages — they cover the full landscape of recruiting trials for each cancer type, including the drugs listed above. Browse trials by disease →

If your oncologist mentioned a drug class by name (BCMA bispecific, GPRC5D bispecific, PSMA radioligand, etc.), you can browse all the recruiting options in that class side-by-side. Browse trials by mechanism →